While bio-pharmaceutical companies are know for their inherent level of business risk, a fair portion of these companies lie in the upper quartile when it comes to the returns they provide for investors. It's important to recognize that the risk to reward profile is not the same for all companies within the bio-pharmaceutical industry, and there is a considerable number of companies that actually present an asymmetric risk to reward scenario that is quite appealing. With that being said, I would like to highlight a clinical-stage bio-pharmaceutical company focused on treating infectious and inflammatory diseases, Dynavax Technologies (NASDAQ:DVAX). Within the last year, DVAX's shares have quite a bit in the market. From a 52 week high of close...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|